Ophthalmic Composition for Hypotonic Therapy Eye Surface Protection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Topical use of hypotonizing ophthalmic formulations for glaucoma treatment leads to side effects on the conjunctiva and cornea, reducing patient compliance due to discomfort and irritation, which can worsen glaucoma progression.
Innovation Solution
An ophthalmic composition containing beta-caryophyllene, optionally with hyaluronic acid, is used to reduce epithelial damage and discomfort caused by hypotonizing therapies, formulated as eye drops or gel without preservatives, for simultaneous, separate, or sequential use with hypotonizing medications.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If hypotonizing ophthalmic formulations are used to treat glaucoma, then intraocular pressure is reduced, but conjunctiva and cornea damage occurs causing discomfort and irritation
Solution Approach 1:
The patent introduces a protective composition containing phospholipids, cholesterol, and tocopherol as intermediary substances that mediate between the hypotonizing medication and the ocular surface. These components form a protective film that reduces direct contact between the medication and conjunctival/corneal cells, thereby maintaining treatment efficacy while minimizing tissue damage and discomfort
Solution Approach 2:
The invention uses a composite formulation combining multiple protective components (phospholipids, cholesterol, tocopherol) in specific proportions. This composite structure creates a synergistic protective effect where phospholipids form the structural matrix, cholesterol stabilizes the membrane, and tocopherol provides antioxidant protection, collectively reducing medication-induced damage
2Reliability
If hypotonizing medications are administered topically, then intraocular pressure control is achieved, but patient compliance decreases due to discomfort
Solution Approach 1:
The protective composition acts as an intermediary that reduces the sensory discomfort associated with medication administration. By forming a soothing film on the ocular surface, it decreases stinging, burning, and irritation sensations, thereby improving patient willingness to continue treatment and maintain compliance
Solution Approach 2:
The patent applies the protective composition beforehand or simultaneously with the hypotonizing medication to cushion the ocular surface against upcoming damage. This preventive approach reduces discomfort before it occurs, ensuring better patient tolerance and long-term compliance with the treatment regimen
Data Source
Figure 1
Figure 2
Figure 3
AI summary
An ophthalmic composition comprising beta-caryophyllene and preferably hyaluronic acid for treating epithelial damage to the sclera or cornea of the eye caused by hypotonizing ophthalmic therapy, and reducing the associated sensation of discomfort and local side effects.